|D4.4 Public event proceedings and videos – Year 2|
The following document provides an overview of the public event proceedings and videos for the second year of the Neuronet initative. The event was organised virtually in October 2020, due to various COVID-19 restrictions throughout Europe that rendered an in-person event impossible to organise.
|10th March 2021|
|D1.4 First report on impact of IMI neurodegeneration portfolio|
The mission of IMI2 is to “improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need”1. Therefore, the ultimate impact that IMI projects can have is to enable the development, approval and access to effective and affordable medicines. There is an implicit assumption that spending on research and development (R&D) through the activities of the IMI neurodegeneration project portfolio might improve innovation in this disease area. Therefore, if we want to assess the impact of the IMI neurodegeneration project portfolio, we will need to identify :
|11th February 2021|
|D4.3 Interim report on dissemination activities|
The present Interim Report on dissemination activities provides a detailed list of communications activities that have been carried out halfway through the coordination and support action (CSA). These include the development of a Communications Experts Community and the creation and maintenance of NEURONET communications channels, as well as participation in two high-profile face-to-face events. The report assesses the impact of undertaken communication activities, analyses compliance with the initial plan and identifies future dissemination opportunities as updates to the communication strategy.
|31st August 2020|
|D3.6 INKB web platform v2: The NEURONET Knowledge Base v2|
Deliverable D3.6 describes the updates made on the design and structure of the NEURONET Knowledge Base since the submission of deliverable D3.1 INKB web platform v1 submitted in month 6.
The aim of the Knowledge Base is to provide a summary overview of the IMI ND programme, in the format of a dashboard, where users can find information about the portfolio of projects (e.g. work plan, deliverables, results, publications, tools developed, etc). It also includes a section with the contact details of project experts in six key areas (ethics, data sharing, regulatory interactions, sustainability, communication and project management). More recently, we have also included the first tools developed by NEURONET, namely the Asset map and the Regulatory and HTA engagement Decision Tool.
|31st August 2020|
|D3.5 First version of guidance on sustainability|
In this report we compile knowledge and information derived from the NEURONET Working Group on Sustainability about the sustainability models used in or applicable to IMI neurodegeneration projects, as well as general lessons learned, as a resource for current and future projects to improve the chances of successful sustainability decisions through the IMI neurodegeneration portfolio.
|16th June 2020|
|D3.2 First version on guidance tools on data/sample sharing and use|
This deliverable focuses on developing specific guidance to aid projects on data sharing policies and tools, incentives, value propositions, infrastructural solutions, etc. With the support of the “Data sharing and re-use” WG, Task 3.2 will develop guidelines aimed at facilitating the sharing of and access to data, biological tools, and other materials amongst IMI projects, as well as with other interested researchers at a European and global level.
|4th June 2020|
|D1.2 Integrated programme analysis|
NEURONET is a Coordination and Support Action (CSA) aiming to support and better integrate projects in the Innovative Medicines Initiative (IMI) Neurodegenerative Disorders (ND) portfolio. WP1 Projects & Impact Analysis is a descriptive and methodological work package (WP) that collects information (e.g. scope, deliverables, funding etc.) about IMI ND projects to enable an integrated view of the IMI ND project portfolio in terms of relative specialisation, timelines, expertise and outputs. As part of WP1 activities, NEURONET conducted an integrated analysis of IMI ND projects at the programme level in order to obtain a first integrated view of the portfolio. This deliverable reports on the approach, methodology and results of the exercise carried out.
|27th April 2020|
|D1.3 Map of relevant initiatives and gap analysis v1|
This deliverable aimed to map the global research landscape for neurodegenerative diseases to understand where the IMI neurodegenerative portfolio fits in globally and to enable a gap analysis with the IMI project portfolio.
The results demonstrated that the scale and volume of global research in comparison to the IMI portfolio is considerable. There was a clear focus on Alzheimer’s disease research, both globally and within the IMI portfolio.
|26th March 2020|
|D2.2 Report #1 on activity of SCB, WGs and TFs|
The NEURONET Coordination and Support Action has the main objective of setting up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide. Deliverable D2.2 Report #1 on activity of SCB, WGs and TFs constitutes a report on the activities of the Scientific Coordination Board and the four Working Groups in the first year of the project (no Task Forces have been established yet).
|26th March 2020|
|D3.4 First version of guidance on standards and practices for protecting data privacy|
Neuronet is a Coordination and Support Action (CSA) aiming to support and better integrate projects in the IMI Neurodegenerative Disorders (ND) portfolio. WP3 Tools and Services aims to develop tools and services to support the IMI ND projects in areas where unmet needs have been identified. One of these areas of unmet need is patient privacy, particularly following implementation of the General Data Protection Regulation (GDPR) in May 2018. Neuronet intends to compile and share learnings on patient privacy, to ensure best practice, reduce duplication of effort and create resources that will be of value to existing and future IMI ND projects.
|2nd March 2020|
|D4.2 Public event proceedings and videos – Year 1|
NEURONET also organises an annual networking and outreach event in collaboration with the leaders of the individual projects, to shine a spotlight on the IMI neurodegeneration portfolio. The event proceedings are then disseminated to the general public through NEURONET’s communication channels, which include a website, regular newsletters and social media feeds. This document provides an overview of the annual event as well as related outreach activities that have been conducted.
|27th February 2020|
|D3.3 First version of regulatory/HTA/payer interaction decision tool|
This deliverable reports on the development of a Decision Tool aimed at identifying the key processes and procedures for engagement with regulatory, HTA bodies, and payers at key points in the development of an asset. The tool will help the IMI ND projects in identifying the most appropriate procedures and ways in which they can interact with different stakeholders, based on the project’s stage of research and type of asset being developed. This will help ensure that the outputs being developed by projects that are part of the IMI Neurodegeneration portfolio are relevant for regulatory and HTA settings, where applicable.
|24th December 2019|
|D1.1 Project outreach and analysis package|
This deliverable reports on the workflow and processes followed by WP1 to develop a full set of dimensions and indicators to be used for the IMI ND integrated portfolio analysis (Task 1.3) and impact analysis (Task 1.4), forming the foundation for all the subsequent tasks and deliverables of WP1 throughout the project duration. Moreover, the overall strategy to obtain information from IMI ND projects is also described.
|26th November 2019|
|D5.1 Initial Data & Knowledge Management Plan|
This first deliverable of WP5 CSA Management & Sustainability (D5.1) constitutes the first version of the Data and Knowledge Management Plan (DKMP) for the NEURONET project, as required by the Innovative Medicines Initiative (IMI) JU guidelines. This DKMP represents a formal document describing in detail how data are handled for the entire duration of the NEURONET project (i.e complete data life cycle). It also outlines the strategies that NEURONET will implement to manage, analyse and preserve data and metadata.
|29th August 2019|
|D3.1 INKB web platform v1: NEURONET Knowledge Base v1|
Deliverable D3.1 describes the design and structure of the NEURONET Knowledge Base, a web platform that will act as a portal for the whole Innovative Medicines Initiative (IMI) Neurodegenerative Disorders (ND) programme. The aim of the Knowledge Base is to provide a summary overview of the IMI ND programme, in the format of a dashboard, where users can find information about the portfolio of projects (e.g. work plan, deliverables, results, publications, tools developed, etc). Furthermore, it will include a section with contact details of experts in key project areas (i.e. ethics, data sharing, regulatory interactions, sustainability, communication and management).
|29th August 2019|
|D4.1 NEURONET communication strategy|
The communication strategy provides a framework with explanations on how the communication and dissemination activities will help NEURONET fulfil its overarching communication aims, ensuring that its goals are clear and achievable. The communication strategy will remain open to changes and undergo updates, enabling it to evolve with the development of the programme and launch of new projects.
|14th August 2019|
|D2.1 Report on establishment and procedures of SCB and foundational WGs|
The deliverable D2.1 Report on establishment and procedures of SCB and foundational WGs constitutes a report on the steps and procedures followed for establishing NEURONET’s Scientific Coordination Board (SCB) and Working Groups (WGs), detailing their scope, membership and procedures
|13th June 2019|